Focusing on MGA, we note that it is mutated or deleted in 53 of 507 (10%) lung adenocarcinoma patients (TCGA) and in 233 of 3696 (6%) patients sequenced through the GENIE project (Figure 1—figure supplement 1A). This evidence concerns the gene MGA and lung adenocarcinoma.